+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TQ05105 Tablets in adults with moderate to severe chronic graft-versus-host disease cGVHD. This open, multi-center Phase II clinical trial focuses on patients who have already received systemic treatments for cGVHD and aims to assess how well this new oral medication works to reduce disease symptoms and improve patient outcomes. Participants will take TQ05105 Tablets twice daily in 28-day treatment cycles. TQ05105 is an oral drug that targets specific pathways involved in inflammation and fibrosis associated with cGVHD. The trial will monitor patients up to 24 weeks for the main response rate and continue follow-up for up to 96 weeks to evaluate longer-term effects, including survival and safety outcomes. During the study, participants will have regular assessments to measure treatment response, side effects, blood counts, and organ function. Researchers will track objective responses, duration of response, survival rates, and adverse events. Participants are expected to be involved in these evaluations for up to two years, allowing for thorough monitoring of the drugs impact and safety over time.

Age: 18Years - 70YearsAll GendersPhase 2
12 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Bladder cancer is a common and serious tumor that originates from the bladders lining, with the majority being non-muscle invasive bladder cancer NMIBC. NMIBC has a high recurrence rate even after initial treatment, making postoperative bladder perfusion chemotherapy important to prevent tumor return. This research evaluates the use of patient-derived bladder cancer organoids to test drug sensitivities and guide individualized chemotherapy, aiming to improve treatment effectiveness and reduce recurrence for bladder cancer patients. The study involves preparing bladder cancer organoids from tumor tissue collected during surgery. Researchers perform drug sensitivity testing on these organoids with various chemotherapeutic agents, including gemcitabine, pirenzolubicin, epirubicin, mitomycin, and doxorubicin. Based on organoid sensitivity results, patients receive bladder perfusion chemotherapy with either sensitive or non-sensitive drugs, or receive BCG vaccine infusions. Treatment schedules include induction perfusion weekly for 4 weeks and maintenance perfusion monthly for 11 months, or BCG infusions following an induction and maintenance regimen over one year. Participants undergo regular clinical assessments including cystoscopy, urine cytology, and imaging as needed to monitor tumor recurrence and progression over up to three years. Researchers analyze one-year and three-year tumor recurrence-free and progression-free survival rates among groups. The study monitors patient compliance, adverse events, and clinical outcomes to assess the value of organoid drug sensitivity testing in guiding personalized bladder cancer perfusion chemotherapy.

Age: 18Years - 80YearsAll Genders
17 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.

Age: 18Years +All GendersPhase 3
217 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.

Age: 18Years +All GendersPhase 3
102 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of edaravone dexborneol sublingual tablets for treating cognitive problems after a stroke in adults aged 40 to 80 years. This exploratory Phase II clinical trial is randomized, double-blind, and placebo-controlled, aiming to compare outcomes between patients receiving the study drug and those receiving a placebo. The study focuses on patients who have had an acute ischemic stroke and developed cognitive impairment. Participants will be randomly assigned to receive either edaravone dexborneol sublingual tablets or a placebo twice daily for 24 weeks. Both groups will follow the same treatment schedule over this period. The trial will monitor and compare the safety and effectiveness of the tablet by assessing cognitive function and other health measures. During the study, participants will undergo evaluations including cognitive tests such as the Vascular Dementia Assessment Scale-cognitive subscale, Mini-Mental State Examination, and Montreal Cognitive Assessment at various times up to 24 weeks. Researchers will also track adverse events, treatment discontinuations, and other stroke-related scales. The total follow-up period for safety monitoring extends to 26 weeks, including after treatment completion or early withdrawal.

Age: 40Years - 80YearsAll GendersPhase 2
21 locations
C

Actively Recruiting

Researchers are evaluating treatments for adults with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This Phase II, randomized, open-label trial compares a combination of Disitamab Vedotin, Sintilimab, and S-1 against Trastuzumab plus chemotherapy with or without Sintilimab as first-line treatments. The study aims to assess which approach offers better results in controlling this type of stomach cancer. Participants will receive one of two treatment combinations. The experimental group is given Disitamab Vedotin intravenously every 3 weeks, Sintilimab intravenously every 3 weeks, and oral S-1 twice daily for 14 days in a 3-week cycle. The comparison group receives Trastuzumab intravenously with an initial loading dose followed by maintenance doses every 3 weeks, combined with chemotherapy drugs such as Oxaliplatin, Capecitabine, 5-FU, or Cisplatin, with or without Sintilimab. Treatments continue as per protocol to evaluate effectiveness and safety. Throughout the study, participants will undergo regular assessments to measure tumor response, progression-free survival, overall survival, duration of relief, and safety through monitoring adverse events. These evaluations include imaging scans to track measurable lesions based on RECIST 1.1 criteria, laboratory tests, and clinical examinations. The total study duration extends up to approximately two years, including follow-up for safety and outcomes, to gather comprehensive data on these treatment regimens.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations
E

Actively Recruiting

Healthy Volunteer

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
26 locations
E

Actively Recruiting

Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.

Age: 18Years +FEMALEPhase Not Applicable
110 locations
E

Actively Recruiting

Researchers are evaluating ISM5411, an oral gut-restricted small-molecule prolyl hydroxylase PHD inhibitor, in adult patients with active ulcerative colitis. The study aims to assess the safety, tolerability, pharmacokinetics, and clinical effects of ISM5411, which may help protect the intestinal lining and reduce inflammation, addressing limitations of traditional anti-inflammatory drugs. This multicenter, randomized, double-blind, placebo-controlled trial focuses on adult patients aged 18 to 75 years. Participants are randomly assigned to one of four groups three groups receive ISM5411 tablets orally once a day for up to 12 weeks, and one group receives a placebo tablet orally once a day for up to 12 weeks. The study compares these groups to evaluate the effects and behavior of ISM5411 in the body. The trial includes various cohorts receiving the experimental drug or placebo, all administered as tablets once daily. During the study, participants undergo regular monitoring for safety and drug effects from week 1 to week 12, including tracking treatment-emergent adverse events, serious adverse events, and laboratory tests such as blood work, urinalysis, coagulation tests, and ECGs. Researchers also measure pharmacokinetic parameters like peak plasma concentration, elimination half-life, and colonic tissue concentration. The entire participation period extends up to 16 weeks, covering treatment and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 2
28 locations

1-10 of 12

1